Joon Ho Park

Joon Ho Park

Auto-generated profile, based on publicly available information

Joon Ho Park

Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, MA, 02139, USA; Koch Institute for Integrative Cancer Research, 500 Main St, Cambridge, MA, 02142, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
JPJoon Ho Park
Joon Ho Park
YJYao Jiang
Yao Jiang
JZJiarong Zhou
Jiarong Zhou
HGHua Gong
Hua Gong
AMAnimesh Mohapatra
Animesh Mohapatra
LZLiangfang Zhang
Liangfang Zhang
Genetically engineered cell membrane–coated nanoparticles enable targeted drug delivery to sites of inflammation.

11 March 2026 in Biomaterials
Verified
Journal Article
Closed access
BJBrandon M. Johnston
Brandon M. Johnston
SDSimone A. Douglas-Green
Simone A. Douglas-Green
JPJoon Ho Park
Joon Ho Park
AGAlan J. Grodzinsky
Alan J. Grodzinsky
PHPaula Hammond
Paula Hammond

5 January 2026 in Regenerative Engineering and Translational Medicine
Verified
Journal Article
Open access
PDF file
JPJoon Ho Park
Joon Ho Park
BJBrandon M. Johnston
Brandon M. Johnston
SDSimone Douglas-Green
Simone Douglas-Green
ZSZavian D. Strom
Zavian D. Strom
AGAlan J. Grodzinsky
Alan J. Grodzinsky
PHPaula Hammond
Paula Hammond
Purpose: Osteoarthritis (OA) is a debilitating disease characterized by degeneration of articular cartilage with no clinically approved treatment available to date despite the multitude of approaches that have been proposed. Two fundamentally different therapeutic strategies are pro-anabolic and anti-catabolic treatments. However, one of the major challenges to developing a successful intervention for OA is the fast clearance of the therapeutics from the joint space, which makes evaluating these proposed strategies difficult. In this work, we utilize a modular cationic dendrimer nanoformulation conjugated with therapeutic proteins which grants them longer retention in joint space and makes comparison of the approaches possible. Methods: Dendrimer conjugated with insulin-like growth factor-1 (dend-IGF1) and interleukin-1 receptor antagonist (dend-IL1RA) were used as representative pro-anabolic and anti-catabolic therapeutics, respectively. Preservation of bioactivity of the final formulations was tested in vitro and ex vivo , and the therapeutic efficacy was tested in vivo in a post-traumatic OA model in rats. Results: Studies in a rat model revealed that both therapeutics when conjugated to the dendrimers show improved pharmacokinetics and inhibited OA progression in vivo . Furthermore, dend-IL1RA showed significant efficacy in pain mitigation as well. This work supports the concept that dendrimer-protein conjugates provided an extended half-life within cartilage tissue that can greatly enhance the treatment efficacy of different types of biologic treatments. Conclusion: Therefore, not only do the formulations studied in this work present promising avenues for OA treatment, but they also open up the possibility of exploring other therapeutics to treat anionic avascular tissues, such as meniscus or cornea, using this platform technology. Lay Summary: More than 650 million people worldwide suffer from osteoarthritis (OA), but unfortunately, there is no clinically approved treatment, and the only standard of care is pain management. Although there are two leading mechanisms of treatment that can be used, one being using pro-anabolic drugs to repair cartilages and the other one being using anti-catabolic drugs that prevents cartilage degradation, these drugs get rapidly cleared from the knee joints after injection. Therefore, in this study, we attached insulin-like growth factor-1 (IGF-1) which is a pro-anabolic drug and interleukin-1 receptor antagonist (IL-1RA) which is an anti-catabolic drug to a positively charged polymer that can stick to the cartilage via charge-charge interaction to prevent these drugs from being rapidly cleared. Our findings reveal that by doing so, the drugs were able to stay within the joint space longer and was able to delay OA progression. Especially, IL-1RA – polymer conjugate was able to significantly reduce pain as well.